GOVX Stock Overview A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
GeoVax Labs, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for GeoVax Labs Historical stock prices Current Share Price US$2.29 52 Week High US$11.18 52 Week Low US$1.09 Beta 3.31 1 Month Change -22.37% 3 Month Change -16.12% 1 Year Change -58.17% 3 Year Change -96.20% 5 Year Change -99.05% Change since IPO -100.00%
Recent News & Updates
GeoVax Labs, Inc. Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Nov 20
GeoVax Labs Regains Compliance with Nasdaq's Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1) Nov 19
GeoVax Labs, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05 GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $4.486846 million. Sep 26
GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million. Aug 29
GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million. Aug 22 See more updates
GeoVax Labs, Inc. Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Nov 20
GeoVax Labs Regains Compliance with Nasdaq's Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1) Nov 19
GeoVax Labs, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05 GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $4.486846 million. Sep 26
GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million. Aug 29
GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million. Aug 22 GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million. Aug 21
GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million. Aug 20
Geovax Labs, Inc. Announces Phase 2 Plans for Gedeptin®? Cancer Therapy Following Clinical Advisory Committee Review Jul 31
GeoVax Labs, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30 GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d) Jun 24
GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1) May 25
Price target increased by 14% to US$120 May 16
GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
GeoVax Labs, Inc., Annual General Meeting, May 23, 2024 Apr 16
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress Mar 29
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System Mar 07
New minor risk - Shareholder dilution Mar 04
Price target increased by 14% to US$120 Mar 03
GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement Feb 17
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster Feb 07 GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement Jan 30
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology Jan 08
New major risk - Market cap size Dec 10
GeoVax Labs Receives a Notice from the Nasdaq Stock Market Dec 09
Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02 Nov 15
New major risk - Revenue and earnings growth Nov 05
GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 01
GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine Oct 31
Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients Sep 20
GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster Sep 12
New major risk - Financial position Aug 11
GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Aug 11
GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia Jul 23
GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023 Jun 13
GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings May 16
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 25
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers Feb 08
Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors Dec 21
GeoVax Labs Receives Non-Compliance Notice From Nasdaq Dec 12
GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors Dec 08
Price target decreased to US$5.50 Nov 16
Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021) Nov 10
High number of new directors Oct 31
GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully Sep 08
Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors Sep 02
GeoVax: Possible Vaccine Advancements In 2 Big Indications Aug 08
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021) Aug 05
GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine Jul 28
GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022 Jun 14
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky May 24
First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021) Apr 28
Insufficient new directors Apr 27
GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022 Apr 20
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 11
Geovax Labs, Inc. Announces Management Appointments Mar 10
GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022 Feb 25
GeoVax Labs, Inc. announced that it has received $9.999998 million in funding Jan 22
GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation Dec 27
GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster Dec 16
GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress Dec 05
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth Nov 27
Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020) Nov 14
GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program Oct 03
Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly Aug 22
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth Aug 14
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.66 loss in 2Q 2020) Aug 13
GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting Jul 24
First quarter 2021 earnings released: US$0.29 loss per share (vs US$2.54 loss in 1Q 2020) May 09
Full year 2020 earnings released: US$2.14 loss per share Mar 25
GeoVax Labs, Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 16
GeoVax Expands and Strengthens Intellectual Property Portfolio Mar 06
Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%? Feb 18
New 90-day high: US$7.71 Feb 17
New 90-day high: US$5.95 Jan 27
GeoVax soars on NIAID grant for COVID-19 vaccine candidate Jan 11
GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development Dec 01
New 90-day low: US$2.73 Nov 10 Shareholder Returns GOVX US Biotechs US Market 7D -2.6% -3.6% -2.4% 1Y -58.2% -2.6% 23.4%
See full shareholder returns
Return vs Industry: GOVX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: GOVX underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is GOVX's price volatile compared to industry and market? GOVX volatility GOVX Average Weekly Movement 22.3% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: GOVX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GOVX's weekly volatility has decreased from 29% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Show more GeoVax Labs, Inc. Fundamentals Summary How do GeoVax Labs's earnings and revenue compare to its market cap? GOVX fundamental statistics Market cap US$21.61m Earnings (TTM ) -US$24.32m Revenue (TTM ) US$3.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GOVX income statement (TTM ) Revenue US$3.09m Cost of Revenue US$22.34m Gross Profit -US$19.25m Other Expenses US$5.07m Earnings -US$24.32m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.58 Gross Margin -622.92% Net Profit Margin -787.08% Debt/Equity Ratio 0%
How did GOVX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 09:09 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources GeoVax Labs, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners null null CG Capital Jason Kolbert D. Boral Capital LLC.
Show 3 more analysts 
